Russia - CIS<\/h1>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t

\n\t\t\t\t

\n\t\t\t\t

\n\t\t\t

\n\t\t\t\t\t

\n\t\t\t\t

\n\t\t\t\t

\n\t\t\t\t\t

\n\n\n\n\n \n \n \n \n \n \n \n

Sr. No.<\/th>\n	Product Name<\/th>\n	Pack Description<\/th>\n	Strength<\/th>\n	Composition<\/th>\n	Therapy<\/th>\n	Formulations<\/th>\n<\/tr>\n<\/thead>\n
1<\/td>\n	Spasgan tab<\/td>\n	6 tablets per Alum\/PVC blister. 1 blister with instruction for use per plastic pack. 10 plastic packs per cardboard pack.\n10 tablets per Alum\/PVC blister. 2 blisters with instruction for use per cardboard pack. 10 blisters with an equal number of instructions per cardboard pack.\n<\/td>\n	metamizole sodium monohydrate 500.0 mg+ pitofenone hydrochloride 5.0 mg+fenpiverinium bromide 0.1 mg<\/td>\n	metamizole sodium monohydrate 500.0 mg, pitofenone hydrochloride 5.0 mg, fenpiverinium bromide 0.1 mg, lactose monohydrate, povidone K-30, magnesium stearate, colloidal silicon dioxide<\/td>\n	non-narcotic analgesic and antispasmodic agent<\/td>\n	metamizole sodium monohydrate 500.0 mg, pitofenone hydrochloride 5.0 mg, fenpiverinium bromide 0.1 mg, lactose monohydrate, povidone K-30, magnesium stearate, colloidal silicon dioxide<\/td>\n <\/tr>\n
2<\/td>\n	Spasgan NEO<\/td>\n	1) 10 tablets in PVC\/PVDC\/aluminum blister. 2 blisters with instruc-tion for use in a cardboard box. \n2) 10 tablets in PVC\/PVDC\/aluminum blister. 10 blisters with an equal number of Instructions for use in a carton pack.\n3) 6 tablets in PVC\/PVDC\/aluminum blister. 1 blister with instruction for use in plastic packaging. \n4) 6 tablets in PVC\/PVDC\/aluminum blister. 1 blister with instruction for use in plastic packaging. 6 plastic packings in a carton pack.\n<\/td>\n	Ibuprofen 400.0 mg +pitofenone hydrochloride 5.0 mg+fenpiverinium bromide 0,1 mg <\/td>\n	Ibuprofen 400.0 mg, pitofenone hydrochloride 5.0 mg, fenpiverinium bromide 0,1 mg excipients (Maize Starch 88.0 mg, Microcrystalline Cellulose 85.9 mg, Sodium starch glycolate (type A) 14.7 mg, Alginic Acid 10.6 mg, Disodium Edetate Dihydrate 0.6 mg, Povidone (PVP K-90) 11.0 mg, Colloidal Silica (Aerosil 200) 7.0 mg, Croscarmellose sodium 4.7 mg, Sodium Lauryl Sulfate 2.4 mg, Magnesium Stearate 5.0 mg, Talc 5.0 mg, coating [Opadry II 85G68918 white (polyvinyl alcohol, 7.4 mg, titanium dioxide 5.76 mg, talc, 3.36 mg, macrogol 2.1 mg, soybean lecithin 0.58 mg) 19.2 mg] \n<\/td>\n	combined analgesic antispasmodic.<\/td>\n	Ibuprofen 400.0 mg +pitofenone hydrochloride 5.0 mg+fenpiverinium bromide 0,1 mg <\/td>\n <\/tr>\n
3<\/td>\n	Spasgan inj<\/td>\n	5.0 ml in a glass ampoule for breaking off white on a plastic tray.\n1 or 5 pallets together with a carton box.<\/td>\n	metamizole sodium 500 mg, pitofenone hydrochloride 2 mg, fenpiverinium bromide 0.02 mg<\/td>\n	metamizole sodium 500 mg, pitofenone hydrochloride 2 mg, fenpiverinium bromide 0.02 mg, water for injection up to 1 ml<\/td>\n	Analgesic non-narcotic and antispasmodic agent.<\/td>\n	metamizole sodium 500 mg, pitofenone hydrochloride 2 mg, fenpiverinium bromide 0.02 mg, water for injection up to 1 ml<\/td>\n <\/tr>\n
4<\/td>\n	Wozulim-N<\/td>\n	human insulin (recombinant) 100 IU\/ml:\ncartridge 3 ml, No. 1, No. 5 in a carton pack;\nsyringe pen Dispopen with a cartridge of 3 ml No. 1, No. 5 in a carton pack;\nbottle 10 ml No. 1 in a carton pack<\/td>\n	human insulin (recombinant) suspension for subcutaneous administration 100 IU\/ml (3.5 mg)<\/td>\n	recombinant human insulin 100 IU (3.5 mg), excipients (glycerol, anhydrous sodium phosphate, metacresol, phenol, protamine sulfate, sodium hydroxide, zinc oxide, hydrochloric acid, water for injection- up to 1 ml<\/td>\n	Hypoglycemic agent, intermediate-acting insulin.<\/td>\n	recombinant human insulin 100 IU (3.5 mg), excipients (glycerol, anhydrous sodium phosphate, metacresol, phenol, protamine sulfate, sodium hydroxide, zinc oxide, hydrochloric acid, water for injection)<\/td>\n <\/tr>\n
5<\/td>\n	Wozulim-R<\/td>\n	human insulin (recombinant) 100 IU\/ml:\ncartridge 3 ml, No. 1, No. 5 in a carton pack;\nsyringe pen Dispopen with a cartridge of 3 ml No. 1, No. 5 in a carton pack;\nbottle 10 ml No. 1 in a carton pack<\/td>\n	human insulin (recombinant) 100 IU\/ml injection (3.5 mg)\n<\/td>\n	human insulin (recombinant) – 100 IU (3.5 mg);\nGlycerol – 16.32 mg, metacresol – 2.50 mg, sodium hydroxide – 0.40 mg, sodium citrate dihydrate – 0.19 mg, zinc oxide – 0.031 mg, citric acid monohydrate – 0.0021 mg, hydrochloric acid – 0.001 ml, water for injection – up to 1 ml.<\/td>\n	Hypoglycemic agent – short-acting insulin<\/td>\n	human insulin (recombinant) – 100 IU (3.5 mg);\nGlycerol – 16.32 mg, metacresol – 2.50 mg, sodium hydroxide – 0.40 mg, sodium citrate dihydrate – 0.19 mg, zinc oxide – 0.031 mg, citric acid monohydrate – 0.0021 mg, hydrochloric acid – 0.001 ml, water for injection – up to 1 ml.<\/td>\n <\/tr>\n
6<\/td>\n	Wozulim-30\/70<\/td>\n	human insulin (recombinant) 100 IU\/ml:\ncartridge 3 ml, No. 1, No. 5 in a carton pack;\nsyringe pen Dispopen with a cartridge of 3 ml No. 1, No. 5 in a carton pack;\nbottle 10 ml No. 1 in a carton pack<\/td>\n	human insulin (recombinant) suspension for subcutaneous administration 100 IU\/ml (4.0 mg)<\/td>\n	human insulin (genetically engineered) – 100 IU (4.0 mg);\nprotamine sulfate – 0.28 mg, zinc oxide – 0.032 mg, metacresol – 1.60 mg, phenol – 0.65 mg, glycerol – 16.32 mg, sodium hydroxide – 0.40 mg, disubstituted anhydrous sodium phosphate – 2, 08 mg, hydrochloric acid – 0.00072 ml, water for injection – up to 1 ml.<\/td>\n	A hypoglycemic agent is a combination of short-acting and intermediate-acting insulins.<\/td>\n	human insulin (genetically engineered) – 100 IU (4.0 mg);\nprotamine sulfate – 0.28 mg, zinc oxide – 0.032 mg, metacresol – 1.60 mg, phenol – 0.65 mg, glycerol – 16.32 mg, sodium hydroxide – 0.40 mg, disubstituted anhydrous sodium phosphate – 2, 08 mg, hydrochloric acid – 0.00072 ml, water for injection – up to 1 ml.<\/td>\n <\/tr>\n
7<\/td>\n	Spasgel<\/td>\n	Gel for external use 2.5%.\n30 g, 50 g and 100 g in an aluminum tube. The tube, along with instructions for use, is placed in a carton box.<\/td>\n	gel for external use 2.5%<\/td>\n	ketoprofen – 2.5 g.\ncarbomer 940 (carbopol 980), methyl parahydroxybenzoate, trometamol, lavender oil, polyester PE 240, ethanol (ethyl alcohol) 95%, purified water.<\/td>\n	Non-steroidal anti-inflammatory drugs for topical use.<\/td>\n	ketoprofen – 2.5 g.\ncarbomer 940 (carbopol 980), methyl parahydroxybenzoate, trometamol, lavender oil, polyester PE 240, ethanol (ethyl alcohol) 95%, purified water.<\/td>\n <\/tr>\n
8<\/td>\n	Glaritus<\/td>\n	Insulin glargine, 100 IU\/ml , 3 ml in cartridges \n1 or 5 cartridges in a PVC\/aluminum foil blister or in a PVC blister pack.\nEach blister or blister pack with cartridge No. 1 or No. 5 in a cardboard box along with instructions for medical use (insert leaflet).\n1 or 5 cartridges per cardboard pack with chrome-ersatz boxboard partitions.\nSyringe pen DispoPen (disposable, pre-filled, for multiple injections) with a built-in 3 ml cartridge.\n1 or 5 DispoPen syringe pens in a blister pack made of PVC film along with in-structions for medical use (insert leaflet) and instructions for using the syringe pen in a cardboard box.\n1 or 5 DispoPen syringe pens in a cardboard box with partitions of chrome-ersatz brand cardboard along with instructions for medical use (insert leaflet) and instructions for using the syringe pen in a cardboard box.\n\n<\/td>\n	Insulin glargine\nsolution for subcutaneous administration \ndosage, 100 IU\/ml <\/td>\n	“Active substance:\nInsulin glargine**\n(Manufacturer Specification) 100 IU**\n(equivalent to 3.6378 mg)\nExcipients:\nGlycerol (85%)\n20.00 mg\nMetacresol\n2,70 mg\nZinc Chloride \n[equivalent to 30 mcg of zinc]\n0,0625 mg \nSodium hydroxide 1M\nq.s.\nto adjust pH to 4.0\nHydrochloric acid 1M\nq.s.\nto adjust pH to 4.0\nWater for injection\nup to 1.0 mL\n<\/td>\n	The drug GLARITUS belongs to the pharmacotherapeutic group: agents for the treatment of diabetes mellitus; insulins and their analogues; long-acting insulins and their analogues for injection.<\/td>\n	“Active substance:\nInsulin glargine**\n(Manufacturer Specification) 100 IU**\n(equivalent to 3.6378 mg)\nExcipients:\nGlycerol (85%)\n20.00 mg\nMetacresol\n2,70 mg\nZinc Chloride \n[equivalent to 30 mcg of zinc]\n0,0625 mg \nSodium hydroxide 1M\nq.s.\nto adjust pH to 4.0\nHydrochloric acid 1M\nq.s.\nto adjust pH to 4.0\nWater for injection\nup to 1.0 mL\n<\/td>\n <\/tr>\n <\/tbody>\n<\/table>\n<\/div><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":" Russia – CIS Sr. No. Product Name Pack Description Strength Composition Therapy Formulations 1 Spasgan tab 6 tablets per Alum\/PVC blister. 1 blister with instruction for use per plastic pack. 10 plastic packs per cardboard pack. 10 tablets per Alum\/PVC blister. 2 blisters with instruction for use per cardboard pack. 10 blisters with an equal … <\/p>\n Continue reading “Russia – CIS”<\/span><\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"parent":10430,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"yoast_head":"\n